Loading...
SONN logo

Sonnet BioTherapeutics Holdings, Inc.NasdaqCM:SONN Stock Report

Market Cap US$8.6m
Share Price
US$1.26
US$20
93.7% undervalued intrinsic discount
1Y-37.6%
7D-69.7%
1D
Portfolio Value
​
View

Sonnet BioTherapeutics Holdings, Inc.

NasdaqCM:SONN Stock Report

Market Cap: US$8.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sonnet BioTherapeutics Holdings (SONN) Stock Overview

A biotechnology company, owns a platform for biologic medicines of single or bifunctional action. More details

SONN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($1,000K)

Negative shareholders equity

Does not have a meaningful market cap ($9M)

+ 1 more risk

SONN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Sonnet BioTherapeutics Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sonnet BioTherapeutics Holdings
Historical stock prices
Current Share PriceUS$1.26
52 Week HighUS$19.30
52 Week LowUS$1.08
Beta1.47
1 Month Change-68.73%
3 Month Change-56.55%
1 Year Change-37.62%
3 Year Change-99.31%
5 Year Change-99.98%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Seeking Alpha • Oct 04

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Clinical-stage drugs company Sonnet BioTherapeutics (NASDAQ:SONN) said it has received notice from the Nasdaq over regaining compliance with the minimum bid price requirement. The notice was received on Aug. 22. The company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. SONN had met the requirement on Sep. 30. Shares were trading -1.35% pre-market. Source: Press Release
Seeking Alpha • Sep 16

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

In a bid to maintain a Nasdaq's minimum price requirement, Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has announced plans of 1-for-14 reverse stock split of its shares on Friday The stock is slated to begin trading on split adjusted basis from Sept. 19, 2022. SONN shares are up 21% pre-market.
Seeking Alpha • Jul 22

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Sonnet BioTherapeutics (NASDAQ:SONN) said a phase 1b/2a trial of SON-080 was authorized to begin in Australia in patients with persistent chemotherapy-induced peripheral neuropathy (CIPN). Peripheral neuropathy is damage to the nerves outside the brain and spinal cord (peripheral nerves) causing weakness and pain, usually in the hands and feet. It can also affect digestion, urination and circulation. Chemotherapy can also cause peripheral nerve damage in patients. SON-080 is a proprietary version of recombinant human Interleukin-6 (rhIL-6), the company noted in a July 22 press release. The study, dubbed SB211, is aimed to provide safety data compared to previous IL-6 products, along with preliminary efficacy. "Interleukin-6 has been extensively studied in cancer patients in the past, so the use of SON-080 in CIPN is expected to provide similar safety, PK, and PD results at low doses," said Sonnet's Chief Medical Officer Richard Kenney. The company noted that recruitment has begun and dosing is expected to begin imminently.
Analysis Article • Dec 19

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

SONNUS BiotechsUS Market
7D-69.7%-3.1%-2.9%
1Y-37.6%26.9%23.5%

Return vs Industry: SONN underperformed the US Biotechs industry which returned 14.8% over the past year.

Return vs Market: SONN underperformed the US Market which returned 11.9% over the past year.

Price Volatility

Is SONN's price volatile compared to industry and market?
SONN volatility
SONN Average Weekly Movement33.8%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: SONN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SONN's weekly volatility has decreased from 42% to 34% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a13Raghu Raowww.sonnetbio.com

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.

Sonnet BioTherapeutics Holdings, Inc. Fundamentals Summary

How do Sonnet BioTherapeutics Holdings's earnings and revenue compare to its market cap?
SONN fundamental statistics
Market capUS$8.60m
Earnings (TTM)-US$13.56m
Revenue (TTM)US$1.00m
8.6x
P/S Ratio
-0.6x
P/E Ratio

Is SONN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SONN income statement (TTM)
RevenueUS$1.00m
Cost of RevenueUS$1.77m
Gross Profit-US$767.53k
Other ExpensesUS$12.79m
Earnings-US$13.56m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.99
Gross Margin-76.75%
Net Profit Margin-1,355.62%
Debt/Equity Ratio0%

How did SONN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/03 09:35
End of Day Share Price 2025/12/02 00:00
Earnings2025/06/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sonnet BioTherapeutics Holdings, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeChardan Capital Markets, LLC